Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AngioSoma, La Jolla Capital form JV to manage Liprostin

Executive Summary

AngioSoma Inc. and La Jolla Capital Partners are creating a joint venture to handle activities for AngioSoma's Liprostin (alprostadil) a liposomal encapsulated prostaglandin e1 for peripheral artery disease.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Joint Venture
    • R&D and Marketing (Licensing)

Related Companies